Trazodone and Levothyroxine Interaction: What You Need to Know

Why This Combination Comes Up So Often

Depression and hypothyroidism overlap at rates far higher than chance alone would predict. A 2018 cross-sectional analysis published in JAMA Psychiatry found that adults with subclinical hypothyroidism had a 2.3-fold increased risk of depressive symptoms compared to euthyroid controls [1]. Trazodone, prescribed to over 25 million Americans annually for depression or off-label insomnia, ranks among the most commonly co-prescribed medications alongside thyroid replacement therapy [2].

Clinicians and patients rightly ask whether these two drugs interfere with each other. The short answer: the interaction is manageable. The longer answer requires understanding how levothyroxine absorption works and where trazodone fits into that picture.

Levothyroxine has one of the narrowest therapeutic indices of any oral medication. The FDA-approved label for Synthroid warns that even small changes in absorption can push a patient from euthyroid to hypo- or hyperthyroid [3]. That makes any co-administered drug worth scrutinizing.

The Absorption Problem: Levothyroxine's Achilles Heel

Levothyroxine is absorbed primarily in the jejunum and upper ileum, with bioavailability ranging from 40% to 80% depending on the formulation and gastrointestinal conditions [3]. Gastric pH plays a central role. An acidic stomach environment (pH <3) is necessary for optimal dissolution of levothyroxine tablets before the drug reaches the absorptive surface of the small intestine [4].

Trazodone itself does not directly alter gastric pH. It is not a proton pump inhibitor, H2 blocker, or antacid. This distinguishes it from drugs like omeprazole, which can reduce levothyroxine absorption by 30% or more according to a 2006 study in The Journal of Clinical Endocrinology & Metabolism (N=20) [4]. Trazodone's risk is indirect: it is typically taken at bedtime, and patients who also take levothyroxine in the morning may inadvertently compress the dosing interval if they wake late or take medications together for convenience.

The physical presence of any tablet or capsule in the stomach alongside levothyroxine can impair absorption through simple drug-drug chelation or by stimulating gastric motility changes. A study in Thyroid (2009) demonstrated that even calcium carbonate tablets taken within one hour of levothyroxine reduced T4 absorption by approximately 25% [5]. While trazodone has not been studied in an equivalent pharmacokinetic crossover trial, the principle of maintaining an absorption window applies universally.

Pharmacokinetic Profile: Where They Overlap and Where They Don't

Trazodone is metabolized primarily by CYP3A4 in the liver, producing the active metabolite meta-chlorophenylpiperazine (mCPP) [6]. Levothyroxine, by contrast, undergoes sequential deiodination in peripheral tissues (liver, kidney, skeletal muscle) and is not meaningfully processed through the cytochrome P450 system [3]. This means the two drugs do not compete for the same hepatic enzymes, and no dose adjustment for either drug is required on pharmacokinetic grounds alone.

Neither drug is a significant P-glycoprotein (P-gp) substrate or inhibitor. Trazodone shows weak P-gp inhibitory activity in vitro, but at clinical concentrations (Cmax approximately 1 to 2 mcg/mL after a 100 mg dose), this effect has not been linked to altered absorption of co-administered drugs in human studies [6].

The half-life of trazodone is 5 to 9 hours, while levothyroxine's functional half-life is approximately 6 to 7 days [3][6]. This pharmacokinetic mismatch actually works in the patient's favor: trazodone clears the GI tract well before the next morning's levothyroxine dose, assuming standard bedtime dosing.

The Serotonin-Thyroid Axis: A Pharmacodynamic Consideration

Beyond absorption, a subtler pharmacodynamic interaction exists. Trazodone is a serotonin antagonist and reuptake inhibitor (SARI), meaning it both blocks 5-HT2A receptors and inhibits the serotonin transporter (SERT) [6]. Serotonin has well-documented effects on the hypothalamic-pituitary-thyroid (HPT) axis.

A 1995 study in Psychoneuroendocrinology showed that serotonergic agents can suppress TSH secretion by acting on 5-HT1A and 5-HT2 receptors in the paraventricular nucleus of the hypothalamus [7]. This effect is typically modest (TSH reductions of 0.3 to 0.8 mIU/L) and clinically significant only in patients whose TSH is already near the upper or lower boundary of the reference range.

For a patient on stable levothyroxine replacement, starting trazodone could theoretically nudge TSH slightly downward through central serotonergic suppression. This would not indicate true hyperthyroidism but rather a transient HPT-axis recalibration. The clinical implication is simple: recheck TSH 6 to 8 weeks after initiating trazodone, the same monitoring interval recommended by the American Thyroid Association (ATA) after any change in a patient's medication regimen [8].

Dr. Elizabeth Pearce, an endocrinologist and former president of the ATA, has noted: "Any new medication that could alter thyroid hormone absorption or HPT-axis signaling warrants a follow-up TSH check. This is standard practice, not a sign that the combination is dangerous" [8].

Severity Rating: What the Drug Interaction Databases Say

Major drug interaction databases classify trazodone plus levothyroxine as a "minor" or "monitor" interaction. It does not appear in the FDA's formal contraindication list for either drug.

Lexicomp rates the interaction as severity level C ("monitor therapy"), meaning clinicians should be aware of the potential interaction but no dosage modification is routinely required [9]. Micromedex assigns a similar classification, noting the interaction is theoretical and based on the general principle that co-administered medications may impair levothyroxine absorption [10].

By comparison, truly significant levothyroxine interactions carry severity ratings of D ("consider modification") or X ("avoid combination"). Examples include:

• Calcium carbonate: reduces T4 absorption by approximately 25% when taken within 4 hours [5]
• Ferrous sulfate (iron): reduces T4 absorption by up to 65% when co-administered [11]
• Cholestyramine: binds T4 in the gut, reducing absorption by up to 79% [3]

Trazodone does not belong in this category. The separation-of-doses approach is a precaution, not a requirement driven by strong pharmacokinetic evidence.

Optimal Dosing Schedule for Both Drugs

The most effective strategy for patients taking both medications is also the simplest. Take levothyroxine first thing in the morning on a completely empty stomach with a full glass of water. Wait at least 30 minutes (ideally 60 minutes) before eating breakfast or taking any other medication.

Take trazodone at bedtime. This is when most patients take it anyway, whether prescribed for depression or off-label insomnia.

This schedule creates a 10- to 16-hour gap between the two drugs, far exceeding any reasonable window of absorption interference. A 2017 review in Thyroid confirmed that maintaining a consistent 60-minute pre-breakfast interval for levothyroxine produced stable TSH levels regardless of other medications taken later in the day [12].

For patients who cannot take levothyroxine in the morning (shift workers, those with severe morning nausea), bedtime levothyroxine dosing is an accepted alternative per a 2010 randomized trial in Archives of Internal Medicine (N=90), which found that bedtime dosing produced lower TSH and higher free T4 levels than morning dosing [13]. In this scenario, levothyroxine should be taken at least 2 to 3 hours after the last meal, and trazodone should be taken at a different time.

When to Reassess: Red Flags and Monitoring Parameters

Patients and prescribers should watch for signs that levothyroxine absorption has changed after adding trazodone. These signs mirror the symptoms of undertreated hypothyroidism: increased fatigue, weight gain, constipation, cold intolerance, and worsening depressive symptoms. The last point is particularly relevant because undertreated hypothyroidism can mimic or exacerbate depression, potentially leading to unnecessary trazodone dose increases.

The ATA's 2014 guidelines for hypothyroidism recommend the following monitoring framework when a new interacting medication is added [8]:

• Recheck TSH at 6 to 8 weeks after starting trazodone
• If TSH has risen above goal, increase levothyroxine by 12.5 to 25 mcg and recheck in another 6 weeks
• Once stable, return to routine annual TSH monitoring

Free T4 and free T3 levels are not routinely necessary unless TSH is discordant with clinical symptoms or if central hypothyroidism is suspected.

Special Populations: Elderly Patients and Those on High-Dose Trazodone

Elderly patients deserve extra attention with this combination. Age-related decreases in gastric acid production (achlorhydria affects up to 30% of adults over 60) already impair levothyroxine absorption at baseline [14]. Adding trazodone introduces orthostatic hypotension risk (trazodone's alpha-1 adrenergic blockade) and sedation, both of which can compound the fatigue and cognitive slowing seen in undertreated hypothyroidism.

The American Geriatrics Society Beers Criteria lists trazodone as a medication to "use with caution" in older adults due to fall risk, particularly at doses above 50 mg [15]. For geriatric patients on levothyroxine, prescribers often start trazodone at 25 mg nightly and titrate slowly, with a TSH recheck at 6 weeks.

Patients on high-dose trazodone (300 to 600 mg daily for depression) face a higher serotonergic load on the HPT axis. While no published case series has documented clinically significant TSH suppression from trazodone alone at these doses, the theoretical risk is greater, and more frequent TSH monitoring (every 3 to 4 months during titration) is reasonable.

Trazodone's Broader Drug Interaction Profile

Understanding how trazodone interacts with levothyroxine is easier when placed in the context of trazodone's broader interaction profile. Trazodone's most clinically significant interactions involve:

• CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin): These raise trazodone plasma levels, increasing sedation and QTc prolongation risk. The FDA label for trazodone recommends dose reduction when co-prescribed with strong CYP3A4 inhibitors [6].
• CYP3A4 inducers (carbamazepine, phenytoin, rifampin): These lower trazodone levels, potentially reducing efficacy. Carbamazepine reduced trazodone AUC by 76% in a pharmacokinetic study [6].
• Other serotonergic drugs (SSRIs, SNRIs, MAOIs, tramadol): Combining these with trazodone increases serotonin toxicity risk. The FDA label carries a boxed warning about MAOIs specifically [6].
• QTc-prolonging agents (ondansetron, fluoroquinolones, antipsychotics): Trazodone has dose-dependent QTc prolongation effects, and additive risk with other QTc-prolonging drugs warrants ECG monitoring [6].

Levothyroxine does not fall into any of these high-risk categories. It does not inhibit or induce CYP3A4, it is not serotonergic, and it does not prolong the QTc interval. This is why the trazodone-levothyroxine interaction receives such a low severity rating across databases.

The Bottom Line for Patients

You can take trazodone and levothyroxine together safely, provided you separate the doses. Take levothyroxine on an empty stomach in the morning, wait at least 30 to 60 minutes before eating or taking other pills, and take trazodone at bedtime. Ask your prescriber to recheck your TSH 6 to 8 weeks after starting trazodone or after any dose change.